EA201790787A1 - Снижение вязкости фармацевтических составов - Google Patents

Снижение вязкости фармацевтических составов

Info

Publication number
EA201790787A1
EA201790787A1 EA201790787A EA201790787A EA201790787A1 EA 201790787 A1 EA201790787 A1 EA 201790787A1 EA 201790787 A EA201790787 A EA 201790787A EA 201790787 A EA201790787 A EA 201790787A EA 201790787 A1 EA201790787 A1 EA 201790787A1
Authority
EA
Eurasian Patent Office
Prior art keywords
viscosity
reduction
pharmaceutical compositions
proposed
pharmaceutical formulation
Prior art date
Application number
EA201790787A
Other languages
English (en)
Other versions
EA033444B1 (ru
Inventor
Кристофер Джеймс Слоуи
Секхар Канапурам
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790787(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201790787A1 publication Critical patent/EA201790787A1/ru
Publication of EA033444B1 publication Critical patent/EA033444B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Abstract

Предлагается способ снижения вязкости фармацевтического состава, в котором используется вспомогательное вещество, выбранного из группы, состоящей из N-ацетиларгинина, N-ацетиллизина, N-ацетилпролина и их смесей, в концентрации, снижающей вязкость в комбинации с терапевтическим белком. Дополнительно, предлагается стабильный фармацевтический состав.
EA201790787A 2014-10-23 2015-10-22 Снижение вязкости фармацевтических составов EA033444B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23
PCT/US2015/056972 WO2016065181A1 (en) 2014-10-23 2015-10-22 Reducing viscosity of pharmaceutical formulations

Publications (2)

Publication Number Publication Date
EA201790787A1 true EA201790787A1 (ru) 2017-08-31
EA033444B1 EA033444B1 (ru) 2019-10-31

Family

ID=54427875

Family Applications (3)

Application Number Title Priority Date Filing Date
EA202191513A EA202191513A1 (ru) 2014-10-23 2015-10-22 Снижение вязкости фармацевтических составов
EA201991447A EA038462B1 (ru) 2014-10-23 2015-10-22 Снижение вязкости фармацевтических составов
EA201790787A EA033444B1 (ru) 2014-10-23 2015-10-22 Снижение вязкости фармацевтических составов

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA202191513A EA202191513A1 (ru) 2014-10-23 2015-10-22 Снижение вязкости фармацевтических составов
EA201991447A EA038462B1 (ru) 2014-10-23 2015-10-22 Снижение вязкости фармацевтических составов

Country Status (17)

Country Link
US (2) US11813328B2 (ru)
EP (2) EP3909611B1 (ru)
JP (3) JP2017531682A (ru)
KR (1) KR102534017B1 (ru)
CN (2) CN107206070B (ru)
AU (2) AU2015335743B2 (ru)
BR (1) BR112017008125B1 (ru)
CA (1) CA2964786C (ru)
CL (2) CL2017000984A1 (ru)
EA (3) EA202191513A1 (ru)
ES (1) ES2964713T3 (ru)
IL (2) IL287947B1 (ru)
MA (1) MA54716A (ru)
MX (2) MX2017005243A (ru)
SG (1) SG11201703152RA (ru)
WO (1) WO2016065181A1 (ru)
ZA (1) ZA201702762B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191513A1 (ru) 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CA3059369A1 (en) 2017-04-28 2018-11-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
MA48461A (fr) 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP3685849A4 (en) * 2017-09-22 2021-12-22 Asahi Kasei Pharma Corporation LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
AU2019297498A1 (en) 2018-07-05 2021-01-21 Bayer Aktiengesellschaft Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CA3141857A1 (en) * 2019-04-23 2020-10-29 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
EP1028748B1 (en) * 1997-11-07 2003-05-02 Chiron Corporation Compositions providing for increased igf-i solubility
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
CA2403962C (en) 2000-03-31 2009-12-15 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability
WO2002038170A2 (en) 2000-11-07 2002-05-16 Chiron Corporation Stabilized inteferon compositions
AU2002332628B2 (en) 2001-08-23 2007-07-26 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
AU2004207003A1 (en) 2003-01-30 2004-08-12 Medimmune, Llc Anti-integrin alphanubeta3 antibody formulations and uses thereof
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1977763A4 (en) * 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
DK2066684T3 (da) 2006-05-11 2012-10-22 Isis Pharmaceuticals Inc 5´-Modificerede bicycliske nukleinsyreanaloge
CA2671538A1 (en) 2006-12-14 2008-06-26 Leonard G. Presta Engineered anti-tslp antibody
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
NZ709704A (en) * 2007-11-30 2017-03-31 Abbvie Biotechnology Ltd Protein formulations and methods of making same
SG2013054218A (en) * 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
AU2010321225B2 (en) * 2009-11-17 2015-12-03 Ipsen Pharma S.A.S. Formulation for hGH and rhIGF-1 combination
ES2716088T3 (es) * 2010-02-04 2019-06-10 Csl Behring Ag Preparado de inmunoglobulina
EP3708190A1 (en) * 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
WO2011109415A2 (en) * 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
MX352823B (es) * 2011-10-28 2017-12-04 Integritybio Inc Formulaciones de proteinas que contienen aminoacidos.
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
EA202191513A1 (ru) 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов
PL3226895T3 (pl) 2014-12-03 2020-12-28 Csl Behring Ag Produkt farmaceutyczny o zwiększonej stabilności zawierający immunoglobuliny
AU2017336673A1 (en) 2016-09-29 2019-04-18 Amgen Inc. Low-viscosity antigen binding proteins and methods of making them
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
KR20170071518A (ko) 2017-06-23
US11813328B2 (en) 2023-11-14
CN107206070A (zh) 2017-09-26
ES2964713T3 (es) 2024-04-09
JP2017531682A (ja) 2017-10-26
JP2020037559A (ja) 2020-03-12
WO2016065181A1 (en) 2016-04-28
AU2015335743A1 (en) 2017-05-04
CA2964786A1 (en) 2016-04-28
US20170333559A1 (en) 2017-11-23
IL251726B (en) 2021-12-01
BR112017008125B1 (pt) 2023-11-21
CA2964786C (en) 2023-10-17
AU2015335743B2 (en) 2020-12-24
JP6965321B2 (ja) 2021-11-10
IL287947A (en) 2022-01-01
JP7411615B2 (ja) 2024-01-11
EP3909611B1 (en) 2023-08-30
EA202191513A1 (ru) 2021-11-30
EA033444B1 (ru) 2019-10-31
MX2017005243A (es) 2017-08-18
MX2021015789A (es) 2022-01-27
MA54716A (fr) 2021-11-17
IL251726A0 (en) 2017-06-29
EP3209332A1 (en) 2017-08-30
EP3209332B1 (en) 2021-05-26
US20240066124A1 (en) 2024-02-29
JP2022009223A (ja) 2022-01-14
EA201991447A1 (ru) 2019-11-29
BR112017008125A2 (pt) 2018-06-19
CN114569716A (zh) 2022-06-03
EP3909611A1 (en) 2021-11-17
AU2021200990B2 (en) 2023-02-16
KR102534017B1 (ko) 2023-05-19
ZA201702762B (en) 2022-12-21
CL2017000984A1 (es) 2018-01-05
EA038462B1 (ru) 2021-08-31
SG11201703152RA (en) 2017-05-30
IL287947B1 (en) 2024-04-01
CL2019002190A1 (es) 2019-11-22
CN107206070B (zh) 2022-01-18
AU2021200990A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MY187540A (en) Compounds active towards bromodomains
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CL2015002897A1 (es) Inhibidores de bace1
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
MX2017013879A (es) Composiciones que comprenden anakinra.
MX2017017119A (es) Formulacion de alta concentracion.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112017004552A2 (pt) composições farmacêuticas
EA201700254A1 (ru) Комбинация
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM